Scott Schneider, 59, misses teaching in-person classes.
Connections with his students and seeing that “ah ha” moment they express when a science concept finally clicks are among the aspects he loves most about the job he’s had for 30 years at Lawrence Technological University in Southfield. Read the story from Michigan Live.
Northwestern Medicine scientists have discovered the pathways through which autoantibodies—immune proteins that mistakenly attack a person’s own body—leak out of blood vessels and cause primary graft dysfunction in some lung transplant recipients, according to findings published in the Journal of Clinical Investigation (JCI).
Primary graft dysfunction (PGD) is a potentially lethal injury to fragile transplanted lungs that occurs in the first days after a transplant operation and affects more than half of lung transplant recipients. The condition is the leading cause of early post-transplantation morbidity and mortality. Read more from Medical Xpress.
ST. LOUIS, MO (11/18/2022) — With a new grant that brings together engineering expertise from Missouri S&T and medical expertise from Saint Louis University’s School of Medicine, researchers are investigating how artificial intelligence (AI) can support matchmaking between donated kidneys and transplant centers to help more patients in need.
Thanks to a $1.8 million grant from the National Science Foundation (NSF) to lead site Missouri S&T, experts in AI and organ transplantation will work to ensure that more kidneys are able to be used by patients who urgently need them. Read more from Saint Louis University.
It has been almost 3 years since the beginning of the COVID-19 pandemic. Much has changed since then, yet still this virus and its variants pose a threat.
In particular, patients treated with dialysis and those living with a kidney transplant must remain diligent to avoid contracting the virus. Read the full story in Healio.
Jenny Tice, 34, makes sure to live each day to its fullest. She is a Bay Area native, works in finance in San Francisco, lives an active lifestyle, and volunteers. However, these milestones wouldn’t have been possible without the help of Carlos Esquivel, MD, chief of the Division of Transplantation at Stanford Medicine Children’s Health. He saved her life, twice.
“When I was 8 months old, I turned jaundiced and wasn’t gaining weight,” she says. “That’s when they found out that there was something wrong.” Read more from Stanford Medicine.
Social determinants of health independently impact post-heart transplant outcomes among Black children.
Social determinants of health (SDOH) independently impact post-heart transplant outcomes among Black children, but not White children, according to the results of a study presented at the American Heart Association (AHA) Scientific Sessions 2022, held from November 5th through 7th, in Chicago, Illinois. Read more from Infectious Disease Advisor.
Tarek Alhamad, MD, has witnessed the grief that patients with a kidney transplant experience when they are facing loss of an allograft.
“It is definitely one of the hardest discussions that we could have as transplant nephrologists with the transplant recipient,” Alhamad, associate professor of medicine and medical director of the kidney transplant program in the division of nephrology at the Washington School of Medicine at St. Louis, told Healio/Nephrology News & Issues. “Going back to dialysis is something that would change their life completely with less quality of life and major dependence on a machine to continue to survive.”
Read the full article in Healio.
A new data report contains key measures of adult heart allocation based on policy changes implemented in October 2018.
The report notes several important trends since implementation, including:
ORLANDO — Patients with chronic kidney disease who choose home dialysis have improved health-related quality of life prior to dialysis dependence compared with patients on other modalities, according to a presenter at ASN Kidney Week.
However, less than half of patients in the study chose home dialysis as their treatment modality. Read more in Healio.
The FDA has approved teplizumab to delay the onset of type 1 diabetes for both adults and children aged 8 years and older with stage 2 type 1 diabetes, according to an agency press release.
Tzield (teplizumab-mzwv, Provention Bio) injection is a humanized anti-CD3 monoclonal antibody designed to delay the development of type 1 diabetes in high-risk adults and children. “Tzield may deactivate the immune cells that attack insulin-producing cells, while increasing theproportion of cells that help moderate the immune response,” according to the release. Read more in Healio.